GSK to sell 2.9% stake in former consumer healthcare business Haleon

  • 📰 SaltWire Network
  • ⏱ Reading Time:
  • 36 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

Business News News

Business Business Latest News,Business Business Headlines

Explore stories from Atlantic Canada.

SaltWire's Atlantic regional weather forecast for October 5, 2023 | SaltWire -GSK intends to sell a 2.9% stake, or about 270 million shares, in its spun-off consumer healthcare business Haleon, the British drugmaker said on Thursday.

The sale will bring down the drugmaker's current 10.3% holding in the Sensodyne maker Haleon, which was spun out and listed on the London Stock Exchange in July 2022. GSK earlier this year sold 240 million shares in Haleon to raise about 804 million pounds , and lowered its stake from 12.9% it initially retained in the business.

The offer price for the sale will be determined by means of an accelerated bookbuild offering process, the company said. As the world's biggest standalone consumer health company, Haleon sells non-prescription drugs, vitamins and oral care products. The company was formed in 2019 with the merger of GSK and Pfizer's consumer healthcare business

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 45. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Newfoundland and Labrador companies travel for Halifax aerospace exhibition Oct. 3\u002D5Explore stories from Atlantic Canada.
Source: SaltWire Network - 🏆 45. / 63 Read more »